© 2021 The Authors, Cis-diammine-dichloroplatinum[II] (cisplatin) is a potent and widely used chemotherapeutic agent with significant efficacy against several forms of cancer in adults and children. Unfortunately, cisplatin has multiple adverse effects and causes irreversible hearing loss (HL) in a large proportion of patients, which severely impacts their quality of life.1 Here, we confirm that treatment with LPT99, a small molecule inhibitor of the apoptosome, preserves hearing levels in a rat model of cisplatin-induced HL and prevents apoptosis in cisplatin-exposed HEI-OC1 cells. These data are encouraging and support the potential of LPT99 for the prevention of the secondary effects of cisplatin for HL., This work was supported by a SPIRALTHCIBERER ER17PE12 grant to SMC. SMC and LRR hold CIBERER contracts. BC, AMC, and JMB contracts were supported in part by projects from FP7-PEOPLE-2013-IAPP-TARGEAR and from MINECO/FEDER SAF2017- 86107-R to IVN.